PRNews

Verdezyne Groundbreaking Ceremony in Malaysia Commemorates Initiation Of The World’s First Biobased DDDA Plant

-VerdePalm Plant to Use Sustainable Palm-based Materials to Manufacture Components of FerroShield™ Dibasic Acid Mixture for Superior Corrosion Inhibition

CARLSBAD, Calif. and KUALA LUMPUR, Malaysia, July 31, 2017 /PRNewswire/ — Verdezyne Inc., a synthetic biology company producing biobased chemicals, announced today that a groundbreaking ceremony was held on July 30th for its VerdePalm plant, Verdezyne’s first commercial-scale renewable chemicals manufacturing facility, at the Bio-XCell premier biotechnology and ecosystem park in Nusajaya, Iskandar, in southern Malaysia. The new facility is designed to produce biobased long chain diacids via fermentation of Verdezyne’s proprietary yeast, which has been engineered to use non-food biomass to produce high value chemicals.  The first product produced at VerdePalm will be dodecanedioic acid (DDDA), a 12-carbon diacid that is a component of many consumer products currently made from petroleum.  DDDA is a main building block of FerroShield™, Verdezyne’s nitrate-free dibasic acid mixture used in a variety of corrosion inhibitor applications.

The groundbreaking ceremony for the VerdePalm plant was co-hosted by Chad Waite, Chairman of the Verdezyne Board of Directors, and YBhg. Tan Sri Dato‘ Abdul Ghani Othman, Chairman of the Board of Sime Darby Berhad, the largest investor in Verdezyne Inc.  Attendees included Malaysian dignitaries and representatives from Verdezyne’s partners, Bio-XCell Malaysia and the Malaysian Biotechnology Corporation.  The Guest of Honor, YAB Dato’ Mohamed Khaled Nordin, Chief Minister of Johor, presented the Officiating Speech.

The VerdePalm plant is expected to be completed in 12-18 months.  VerdePalm will be the world’s first biobased plant for DDDA production.  “Importantly, the starting yeast will be made from the spent biomass that results from palm oil processing,” Waite stated.  “Crude palm oil and palm byproducts, as well as other plant-based raw materials, will be used to produce approximately 6,000 metric tons of industrial grade DDDA each year.  Verdezyne’s technology will enable a very low-value by-product of palm oil processing to become a high-value “green” product that reduces the use of petroleum.” 

“We are excited that a product made by Verdezyne and our Malaysian partners will be shipped around the world to be used as an alternative to the typical petroleum-derived intermediate chemicals,” said E. William Radany, Ph.D., President and CEO of Verdezyne. “The VerdePalm plant is part of our comprehensive strategy of expansion into Asia, and represents a major step toward our goal of replacing petroleum-derived chemicals with renewable drop-in replacements,” he noted.

“Malaysia is proud to host Verdezyne’s first commercial manufacturing plant, which is located at the Malaysin Bio-XCell park.  I believe the eco-system provided by the park will be an excellent fit for the VerdePalm facility.  Malaysia will continue to commit to the ongoing advancement of biotechnology in the country.  The groundbreaking ceremony signifies Verdezyne’s readiness to work with Malaysia and marks another milestone in our quest to add value to the palm industry using biotechnology as a catalyst,” said Zainal Azman B. Abu Kasim, Senior Vice President of BioIndustrials, Bioeconomy Corporation in Malaysia.

DDDA is a key component of FerroShield, which can be used in numerous corrosion inhibitor applications including metalworking fluids, engine coolants, metal cleaners, die cast release agents, and aqueous hydraulic fluids.  “Marketing of FerroShield was launched in February of this year,” Dr. Radany added. “The rust inhibition industry is in need of a high-performing dibasic acid mixture that can be easily incorporated into existing customer formulas.  We foresee strong demand for FerroShield in a number of countries in Asia and Europe, as well as in the U.S. and Canada.”

About Verdezyne 
Verdezyne is a synthetic biology company offering biobased chemicals manufactured via fermentation of its proprietary yeast cells. The company has two commercial products, BIOLON™ DDDA (dodecanedioic acid) and FerroShield™ dibasic acid mixture.  Current investors in Verdezyne include BP Ventures, DSM Venturing B.V., OVP Venture Partners, Monitor Ventures, and Sime Darby. For more information, visit www.verdezyne.com or connect with the company on Twitter, LinkedIn or Facebook.

For samples, orders or more information about Verdezyne’s FerroShield, please contact:

Verdezyne Media Contact:

Jenna Ngian 
Vice President, Global Sales and Marketing
JNgian@Verdezyne.com  
+1-760-707-5288 

Logo – https://mma.prnewswire.com/media/414701/Verdezyne___Logo.jpg

PRNews

Redleaf Forming a “miniature United Nations”

SHANGHAI, July 28, 2017 /PRNewswire/ — Shanghai Redleaf International Women’s and Children’s Hospital launched their fourth anniversary celebrations with a ceremony at 11am Sunday in the main lobby of the hospital. Redleaf babies of various nationalities came together to celebrate the birthday of those babies born in July, as well as the birthday of Redleaf. The Hospital donated an additional one million yuan to the existing Redleaf Award created by the Shanghai Association of Medical and Hygiene Development Funds, to support and reward excellent gynecologists, pediatricians and related medical professionals in Shanghai. The hospital also presented a donation of one hundred thousand yuan to Hong Kong charity, Principal Chan’s Free Tutoring, which provides free tutoring and other education assistance to children of low-income families in Hong Kong. Taiwanese musical genius, deaf pianist Hsu Che-cheng, otherwise known as Modern Day Beethoven, played and sang such songs as “Qin ai de Xiaohai”, to express the sacredness of human life and focus on children’s development. Carnival activities were held in the afternoon, and all proceeds of a garden sale were donated to the Shanghai Song Qingling Foundation.


Shanghai Redleaf International Women’s and Children’s Hospital, forming a “Miniature United Nations”

As a medical institution focused on the needs of the expatriate community, Shanghai Redleaf International Women’s and Children’s Hospital has seen the birth of over 1800 infants of varying races and nationalities, resembling a miniature United Nations. The 130 medical professionals at Redleaf hail from such countries and regions as the USA, the Philippines and Taiwan, and provide Chinese and English bilingual services to Redleaf families. This has led parents of over one hundred nationalities to choose Redleaf, creating a perfect example of non-governmental diplomacy, bringing people of different backgrounds closer together.

This series of events was hosted by renowned media personality Yang Jinlin. Reflecting the spirit of the medical profession, doctors and families at Redleaf have developed strong bonds of mutual trust and support. In the case of a mother whose womb had not fully developed and whose foreign-national baby was born prematurely at only 1.810kg with extremely unstable blood sugar levels, they were able to nurse the infant back from the brink and save its life. Dr Carenia Kuan from the USA has 30 years experience as a pediatrician. Her Pediatrics and New Birth Pediatrics teams at Redleaf share a wealth of experience as well as being very international.

Redleaf also offers highly personalised post-natal service, including comprehensive infant care as well as care and support for new mothers. Flower arrangements, bookmark decoration and handcraft discussions are some of the activities that await new mothers as they enjoy their month’s rest, which is a kind of postnatal care in China. Attention to every detail ensures that new families find the feeling of a real home at Redleaf.

A lot has changed in four years as Redleaf has constantly improved and sharpened every aspect of its service, all the while adhering to its mission to lead the way in the development of the industry and provide the highest quality in medical service. Redleaf stands ready to face future growth alongside all the Redleaf families.

More about Redleaf:

Redleaf is a specialist hospital created to the global professional risk management standard DNV.GL (Det Norske Veritas), with an international team providing top-quality medical service to women and children. Gynecology, Obstetrics, Mammography, Newborn Pediatrics, Pediatrics, Children’s General Practice, Post-Natal Care, and Early Childhood Development form the core activities of Redleaf, while the addition of cosmetic and corrective procedures ensure the Redleaf is a comprehensive medical facility for new mothers and newborn infants alike. There are six LDR (labour, delivery, recovery) birthing suites, including two with water birth facilities. In addition there are a further twelve LDRP (labour, delivery, recovery, post-natal) combined birthing suites.

In terms of facility management, Redleaf leads the way in China by making use of the high-quality, paperless, international-standard management system SAP. Technological synergies and smart IT solutions ensure a better standard of service to Redleaf families.

For more information about Redleaf, please read http://www.redleafhospital.com/

For further consultation or inquiry, please contact:

Address: No.1209 Middle Huaihai Rd, Xu hui District, Shanghai
 24 hrs Hotline: +86-21-6196-3333
 General Tel: +86-21-6196-1133
Mailbox: cs@redleafhospital.com

View original content with multimedia:http://www.prnewswire.com/news-releases/redleaf-forming-a-miniature-united-nations-300495105.html

PRNews

OrthoAccel Technologies, Inc. Names Orthodontic and Dental Industry Executive David Josza as CEO

HOUSTON, July 26, 2017 /PRNewswire/ — OrthoAccel® Technologies, Inc. announces that its board of directors has named David Josza, an orthodontic and dental industry senior executive with more than 25 years of experience, as CEO effective August 1, 2017. A privately owned medical technology start-up, OrthoAccel recently launched its third-generation vibratory orthodontic device AcceleDent® Optima™ that enables orthodontists to achieve more predictable outcomes. AcceleDent Optima is an FDA-cleared, Class II medical device that is clinically shown in randomized control trials to speed up orthodontic treatment by as much as 50 percent while reducing discomfort by up to 71 percent during treatment.

“OrthoAccel is a market leader in accelerated orthodontic technology and I am delighted to lead the company’s next phase of growth and innovation,” said Josza. “This is an exciting stage in OrthoAccel’s trajectory and, based on the feedback of orthodontists and patients who have experienced the new AcceleDent Optima, there is significant opportunity for growth ahead for this best-in-class treatment technology.”

Josza most recently served as corporate vice president and general manager for Zimmer Biomet Dental, a leading global manufacturer of musculoskeletal devices. He joined Zimmer in 2015 when the company acquired his previous firm, Biomet, Inc., and Josza was tapped to lead the complex acquisition integration. Among his accomplishments, he successfully implemented synergistic cost-saving initiatives and cross-selling opportunities that yielded significant profit increases and growth.

Prior to the acquisition, Josza had a 14-year career at Biomet 3i, a global implant and oral reconstructive supplier, most recently serving as vice president of the Americas. As a member of the executive board, he was responsible for developing and delivering the company’s annual strategic plan.

Additional accomplishments at Biomet included developing and leading a variety of significant revenue growth initiatives, including capturing the market leader position in Latin America. Another key accomplishment was the commercialization of a new digital product line, with a specialized sales team and a technical service support function that grew incremental revenue by $2 million in its first year.

In addition to his leadership roles at Zimmer and Biomet, Josza’s in-depth experience includes previous business development, strategic planning and management responsibilities at Henry Schein, Inc. and Stryker Corporation.  

“We are excited to welcome David and recognize that his in-depth experience in dental and medical industries, combined with his many successes as a strategist and business developer, provide an excellent leadership platform for his role at OrthoAccel Technologies,” said Brian R. Smith, chairman of OrthoAccel’s board of directors and managing director of S3Ventures.

The leader in accelerated orthodontics, OrthoAccel has received numerous business and medical design awards that reflect the company’s success in commercializing its patented SoftPulse Technology® for clinical application. AcceleDent has been recognized as the preferred accelerated orthodontic treatment solution by orthodontists participating in surveys conducted by industry journals Orthotown and the Journal of Clinical Orthodontics.

For more information about OrthoAccel and the company’s innovative orthodontic solutions, visit AcceleDent.com.

About OrthoAccel® Technologies, Inc.
OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the creation, manufacturing, marketing and sales of innovative solutions that enhance dental care and orthodontic treatment. Among the company’s innovations is AcceleDent® Optima™, an FDA-cleared, Class II medical device that employs patented SoftPulse Technology® that is demonstrated to speed up bone remodeling. These safe and gentle vibrations accelerate tooth movement by as much as 50 percent and reduce discomfort associated with orthodontic treatment by up to 71 percent. Leading orthodontists from around the world report increased mechanical efficiency with orthodontic appliances and improved predictability of clinical outcomes with AcceleDent.  OrthoAccel, the Leader in Accelerated Orthodontics, is ranked on Deloitte’s 2016 Technology Fast 500 as one of the fastest growing companies in North America. OrthoAccel is based in Houston, Texas and maintains a global presence through its EMEA office in Essen, Germany. To learn more about OrthoAccel’s focus on improving the journey to healthy, beautiful smiles, visit AcceleDent.com.

Source: OrthoAccel Technologies, Inc.

PRNews

Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment

CGI’s technologies provide valuable insights across cancer diagnostics through the accurate and sensitive quantitation of clinically relevant genomic signatures & biomarkers from both blood and tissue samples

SANTA CLARA, California, July 26, 2017 /PRNewswire/ — Based on its recent analysis of the precision oncology industry, Frost & Sullivan recognizes Cancer Genetics, Inc. (CGI or the Company) with the 2017 North American Frost & Sullivan Award for Technology Innovation. CGI’s leading-edge technology platforms and comprehensive menu of diagnostic services enhance precision oncology by enabling earlier cancer detection, improving treatment management, and aiding the development of novel cancer therapies. The Company’s genomic products and services not only present diagnostic, prognostic, and theranostic information for routine clinical care, but also facilitate and accelerate drug development programs seeking to deliver targeted, more effective and safer drugs to market more quickly. With its comprehensive suite of both off-the-shelf and proprietary tests, technology-agnostic approach, global infrastructure, and extensive research collaborations, CGI is at the forefront of enabling precision medicine in oncology globally, from bench to bedside.

“CGI has a wide variety of assays for genomic and immuno-oncology related biomarkers, applicable across several therapeutic areas, including hematological malignancies, solid tumors, and hereditary cancers,” said Frost & Sullivan Research Analyst Vandana Iyer. “The Company offers a broad range of laboratory services that provide critical genomic and biomarker information for patient care and for clinical trials being performed by biotech and pharmaceutical companies. CGI’s recent launches of cutting edge tests, its ability to partner with innovative companies, and its extensive research collaborations with leading academic institutions and cancer centers are a testament to the value and depth of CGI’s commitment to driving industry innovation.”

Some of CGI’s prominent and recently launched technologies include:

  • Complete::IO™ is a unique and in-depth flow cytometry panel supporting informed therapeutic decisions and assessment of potential toxicities for novel immuno-oncology (IO) therapies in blood cancers and solid tumors.
  • Focus::Oncomine™ is capable of simultaneously testing DNA and RNA, enabling the detection of various types of genomic alterations in a single workflow that requires minimal sample quantities and boasts a rapid turnaround time. The Focus::Oncomine™ assay can detect thousands of clinically and pharmacologically relevant biomarkers in solid tumors, making it a valuable tool for clinicians and biopharma.
  • Focus::Lymphoma™ is the most comprehensive next generation sequencing (NGS) panel for B-cell lymphomas in the field.  Focus::Lymphoma™, sequences 220 clinically-actionable genes, allowing clinicians to determine the most effective treatment management for patients. Focus::Lymphoma™ is also offered to biotech and pharmaceutical companies to power efficient clinical trials focused on B-cell lymphomas.
  • Focus::Renal™ is a highly-sensitive NGS panel that provides thorough information for the diagnosis, prognosis and therapy selection in renal cancers.  In a single test, Focus::Renal™ is able to detect mutations in 76 renal cancer-related genes, as well as genome-wide copy number changes, and critical single nucleotide polymorphisms (SNPs). Focus::Renal™ is the only NGS panel of its type, as it is disease-focused, and has been developed through collaboration with leading cancer centers and academic institutions, including MSKCC, Cleveland Clinic, Huntsman Cancer Center at University of Utah, and University Hospital of Paris.
  • Liquid::Lung-cfDNA™ is a CLIA-validated, multi-gene NGS panel for lung cancer liquid biopsies. The test can detect lung tumor-derived cell-free DNA (cfDNA) obtained from a single blood draw, and analyzes frequently-mutated SNPs and short indels in 11 genes with significant clinical relevance to non-small cell lung cancer (NSCLC). This groundbreaking assay is highly sensitive, with a limit of detection (LOD) as low as 0.05% or 1 mutant copy of DNA in a background of 2,000 wild-type copies of DNA.
  • Focus::HERSite™ is a hereditary cancer test that focuses on breast and ovarian cancers. The test analyzes the 16 genes most commonly associated with breast and ovarian cancers and provides in-depth coverage of BRCA1 and BRCA2.
  • Oncomine Dx Target Test is the first NGS-based companion diagnostic (CDx) test that simultaneously screens tumor samples for biomarkers associated with 3 FDA-approved therapies for non-small cell lung cancer (NSCLC). CGI is one of the first laboratories, and one of only three in the United States, to offer the Oncomine Dx Target Test.

CGI has established a global footprint with a presence in the United States, India, and China. The Company’s infrastructure, which has been developed through strategic acquisitions, and its unique business model, which incorporates routine clinical testing for cancer patients and fee-for-service solutions for biotech and pharmaceutical companies, have positioned it uniquely for diversified growth and access to the oncology community. These factors have supported the Company’s successful development of a durable business model through which to commercialize its oncology programs and testing capabilities.

“CGI is a technology-agnostic company with comprehensive diagnostic capabilities utilizing various platforms, including next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, microarrays, RT-PCR, and flow cytometry. The Company boasts full NGS capabilities with both Illumina and Thermo Fisher platforms, offering a mix of proprietary panels and off-the-shelf assays,” noted Iyer. “CGI has several ongoing research collaborations with leading oncologists and cancer centers in both solid tumors and hematological malignancies, including kidney cancer, leukemia, non-Hodgkin’s lymphoma, and HPV-associated cancers. The Company constantly strives for diversity and innovation, and has successfully achieved a balance between the two.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

ABOUT CANCER GENETICS, INC.

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Media Contact:
Panna Sharma
Cancer Genetics, Inc.
Tel: 201-528-9200
Email: panna.sharma@cgix.com

Investor Relations Contact:
Richard Moyer
Cameron Associates
535 Fifth Ave., New York, NY 10017
Tel: 212-554-5466
Email: richard@cameronassoc.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Andrea Steinman
P: 210.477.8425
F: 210.348.1003
E: andrea.steinman@frost.com

PRNews

Survey Finds 68% of Healthcare Respondents Not Familiar with Indoor Location Technologies

LONDON, July 26, 2017 /PRNewswire/ — In a recent B2B technology survey of 455 U.S.-based companies across nine verticals, ABI Research finds that only 32% of respondents are familiar with indoor location technologies and their cost saving benefits. The findings show a disconnect between the healthcare industry’s evident need for an asset tracking solution and their willingness to implement one. Only 2% of healthcare respondents had plans to deploy an indoor location solution within the next twelve months.

“The healthcare industry could see significant returns on investment by tracking assets such as infusion pumps across facilities, especially as medical devices become increasingly advanced and more expensive,” says Samuel McLaughlin, Research Analyst at ABI Research. “There is reluctance within healthcare to deploy asset tracking solutions, despite the potential to save both money and lives. Installation expenses can be high if the solution is not compatible with the hospital’s already-existing network infrastructure and regulations. Indoor location vendors must demonstrate they can offer standards-based systems which can support interoperability features, resulting in easier installation and reduced upfront costs.”

Multiple industry sources estimate that between 10% and 20% of hospital inventory is stolen or lost each year.  This could be partly attributed to healthcare personnel favoring certain equipment and keeping it in areas where only they can access it, rather than where it should be stored. Typical assets that might be tracked in a hospital include ventilators, dialysis machines, heart rate monitors, wheelchairs, and IV pumps. One hospital alone has estimated the yearly cost of replacing IV pumps at US$70k.

Adoption of new and emerging technologies has been traditionally slower in healthcare compared to other verticals, often due to funding issues and cost-saving measures at a government or organizational level. “Recent breaches in security in healthcare systems due to antiquated systems across the world should serve as a wake-up call in hospital organizations to embrace emerging technologies sooner rather than later,” concludes McLaughlin.

These findings are from ABI Research’s Industry Survey: Transformative Technology Adoption and Attitudes report. This report is part of the company’s Location Technologies research service, which includes research, data, and analyst insights.

About ABI Research

ABI Research stands at the forefront of technology market research, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                               

EMEA/APAC

Deborah Petrara                       

Denise Duffy

Tel: +1.516.624.2558                 

Tel: +44.203.326.0142

pr@abiresearch.com                  

duffy@abiresearch.com
PRNews

Early Treatment Is Revolutionizing Outcome Of Burn Scars

Lasers are improving severe scars and pain in Military personnel and burn victims

BURLINGTON, Massachusetts, July 25, 2017 /PRNewswire/ — Early treatment of burn scars with lasers is revolutionizing the outcome of many burn and trauma scar patients. In the past, doctors were taught to wait at least a year before treating burn and trauma scars, but according to Jill Waibel, MD, “That’s really counterintuitive, because the scars get worse. These patients can have horrific, disfiguring, painful contracture scars that form and a lot of our patients are children. We’ve seen that when you go in early, they need less surgery and less laser treatment.”

Laser devices, such as the Lutronic eCO2 laser, originally designed to treat wrinkles and acne scars, are found to have the capability to also improve disfiguring burn scars and other scars, as well as significantly reduce pain in these patients. Jill S. Waibel, MD, world renown Dermatologist, recently completed a clinical trial with Lutronic Aesthetics, proving early scar treatment with lasers is successful and she has been using this approach in practice and with her work on military personnel with battle scars for the last four to five years. Dr. Waibel has also helped many children and people of all ages with burn scars, surgery scars and scars of all types and shares her knowledge with other physicians around the globe.

“I believe we were the first to treat a burn survivor with fractional ablative CO2 in 2011. This is the first randomized control study in severe trauma patients to show early intervention with the Lutronic eCO2 prevents scarring when used within the first 3 months after burn injury. This information could potentially help patients live a better quality of life.” Jill S. Waibel, MD

Dr. Waibel will be discussing the topic “Early Intervention – New Paradigm in Treatment of Burn Scars” in a live Webinar on July 27th. For more information or to register, please visit www.usa.lutronic.com.

About Lutronic 
Lutronic, a leading innovator in advanced aesthetic and medical laser technology, was established over 19 years ago to bring state-of-the-art innovative, yet affordable devices to the worldwide aesthetic community.  All systems optimize outcomes for a wide variety of conditions and treatments including melasma, burn scars, tattoo removal, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/face contouring, chronic pain, healing and more.

Devoting more than 20% of revenue to R&D, Lutronic holds more than 200 current and pending patents worldwide. With more than 270 employees worldwide, Lutronic has offices in the US, Korea, China and Japan, a world-wide network of distributors and a focused R&D center in Korea.

For more information about LUTRONIC, visit: www.lutronic.com

If you would like more information about this topic, please contact Rachel Deschamps at 603-560-5103 or email at rdeschamps@lutronic.com.

Contact

Rachel Deschamps

Cell

603-560-5103

Email

rdeschamps@lutronic.com

Website

www.usa.lutronic.com
PRNews

U.S. FDA Determines Celliant (R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

– Hologenix, LLC’s technology is first of its kind to secure joint FDA designations 

– Celliant-engineered products clinically proven to promote increased localized blood flow

– FDA determination to usher in new era of performance fabrics, responsive textiles

LOS ANGELES, July 25, 2017 /PRNewswire/ — Hologenix, LLC, maker of Celliant, the world’s most advanced, clinically tested responsive textile technology, announced today that the U.S. Food and Drug Administration (FDA) has determined Celliant products are medical devices and general wellness products, as defined in Section 201(h) of the Federal Food, Drug and, Cosmetic Act. According to the FDA, Celliant products were determined to be medical devices because they temporarily promote increased local blood flow at the site of application in healthy individuals.


PureCare Elements: Lumen® Premium Celliant® Sheet Set: The first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant: Uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster.

ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot: A ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017

Salewa Puez TirolWool Celliant Half Zip Jacket: Bends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017

“Celliant-engineered products are the first of their kind that the FDA has designated as medical devices,” said Seth Casden, Hologenix CEO. “Our technology can be used in everyday products — t-shirts, clothing, bedding, even airplane seats — to create an increase in local blood flow thereby increasing energy, boosting performance and speeding muscle recovery.”

“We believe that Celliant is a truly disruptive technology that has transformational applications for textiles,” Casden said. “We’re currently evaluating additional applications of Celliant in the healthcare space, where, for example, people who suffer from diabetes might benefit from increased blood flow to body tissue.”

Celliant-engineered products harness and recycle the natural heat emitted by human beings to boost performance and rebuild and recharge the human body after physical activity and while you sleep. Celliant is made of a patented blend of thermo-reactive minerals infused into the core of fiber used to create all types of textiles and fabrics so it does not wash or wear out. Products made with Celliant fabric absorb and convert body heat into infrared energy (IR) that is recycled back into skin and tissue in a safe, natural way. IR is a vasodilator, increasing blood flow to tissue and muscles throughout the body, which delivers vital nutrients and oxygen to the cells. The effect is clinically proven to help the body:

  • increase energy, endurance, stamina and performance,
  • recover faster from physical activity,
  • promote restful sleep and increased comfort.

Celliant is used in a diverse range of textiles and applications – apparel, bedding, wetsuits and veterinary products, including:

  • SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant which uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster;
  • Salewa Puez TirolWool Celliant Half Zip Jacket that blends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017;
  • ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot, a ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017;
  • PureCare Elements: Lumen® Premium Celliant® Sheet Set, the first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

“Science has shown that infrared energy increases blood flow, improves muscle recovery and reduces long-term pain,” said Dr. Michael R Hamblin, principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital. “The FDA’s determination of Celliant products as medical devices and general wellness products will likely spur interest in infrared technologies and further development of garments and wraps that can positively impact people’s well-being.”

Celliant has been extensively researched, developed and clinically tested for both durability and effectiveness. Prominent institutions have conducted nine clinical trials to evaluate Celliant’s performance including University of California Irvine, University of Calgary, UCI Long Beach Veterans Affairs Medical Center, Texas A&M University, Loyola University Chicago and Exponent. Celliant technology has been shown to increase tissue oxygen levels by eight percent at the site of applicationi. Click here for NIH independent study on the benefits of IR on recovery.

About Celliant®
Celliant is a revolutionary, patented technology that harnesses and recycles the body’s natural energy through the medium of fibers. Celliant’s applied science utilizes a blend of minerals and proprietary ingredients that are embedded into the core of the fiber. Use of products containing this technology has been clinically proven to enhance tissue oxygen levels, improve athletic performance, sleep quality, health and wellness. Fibers, yarns and fabrics with Celliant technology can be found in some of the world’s most recognized name brands. For more information, visit www.celliant.com.  

About Hologenix, LLC
Founded in 2002, Hologenix, LLC, maker of Celliant technology, is committed to creating, developing and bringing to market products that enhance people’s lives through new materials. They strive to deliver the future of healthy innovation through a variety of consumer categories. In addition to the United States, Celliant is designated as a Class I medical device in Canada, European Union, Australia and New Zealand. The Company continues to explore new territories and is currently running FDA-focused, clinical trials to expand into the medical product arena.

i Dr. Ian Gordon – University of CA, Irvine, Effect of Garment with 42% Celliant Fiber on TCP02 Levels and Grip Strength in Healthy Subjects. 2010

Contact: Julia Moore, +1-212-445-8160, Julia.Moore@webershandwick.com

Photo – http://mma.prnewswire.com/media/538683/PureCare_Sheets.jpg
Photo – http://mma.prnewswire.com/media/538684/Xcel_Infinity_Comp_Full_Suit.jpg
Photo – http://mma.prnewswire.com/media/538685/Tecnica_Mach_1_Pro_Women_Ski_Boot.jpg
Photo – http://mma.prnewswire.com/media/538686/Salewa_Puez_TirolWool_Celliant_Half_Zip_Jacket.jpg
Logo – http://mma.prnewswire.com/media/538687/Celliant_Logo.jpg 

PRNews

Healthy Flight Recipe at 30,000 feet from Dr. Mehmet Oz with Turkish Airlines’ Fly Good Feel Good Project

“The Dr. Oz Show” Producer Led the Way by Hosting a Surprise In-Flight Show on Healthy Eating and Lifestyle with Passengers of Flight TK1 from Istanbul to New York

ISTANBUL, July 25, 2017 /PRNewswire/ — Turkish Airlines is collaborating with Dr. Mehmet Oz, the producer and host of world-renowned “The Dr. Oz Show”, on its “Fly Good Feel Good” project, aiming to provide an even more comfortable and healthy travel experience to its passengers. Dr. Oz gives advice to the passengers of Turkish Airlines, the airline flying to more countries than any other airline in the world, on healthy eating and exercises.

The collaboration between Turkish Airlines, Turkey’s National Flag Carrier airline, and Dr. Oz is part of “Fly Good Feel Good” project, which was created to improve the brand experience Turkish Airlines provides to its passengers. The project features short videos with expert advice presented on the Turkish Airlines official website, social media accounts and in-flight entertainment systems, and printed papers.

With help from Turkish Airlines pilots, cabin crew and the Flying Chef of flight TK01 from Istanbul to New York on July 23, Dr. Oz surprised passengers before filming content for his daytime show and the “Fly Good Feel Good” project. As part of this special flight experience, Dr. Oz entertained some 300 passengers of this special flight with health-inspiring gifts and messages over the in-flight entertainment system.

“Making our passengers’ flight experience more comfortable and enjoyable by continuously improving our brand experience is one of our top priorities.” Mr. M. Ilker Ayci, Chairman of the Board and the Executive Committee of Turkish Airlines, said. “How a person feels is just as important as our award-winning service quality. Dr. Oz will create a special atmosphere onboard where our passengers will better feel the privilege of flying with Turkish Airlines.”

“Turkish Airlines is world-renowned and awarded for its high quality service and perfect catering. “Fly Good Feel Good” is, too, an impressive project mindful of the health and wellness dimension of airline travels. I believe that this project is a great example of the attention put on the passengers by bringing the brand experience of Turkish Airlines to a higher level.”

The collaboration with Dr. Oz is the next phase of the Fly Good Feel Good project, which addresses all actions to be taken before, during and after flight in order to make passengers have a good flight in all aspects based on a good flight experience.

As part of the “Fly Good Feel Good” project, Turkish Airlines has also initiated the volunteer-based “Flying Doctor” practice for when an on-board doctor is needed, which enables physicians who register with the program and gain extra miles on their flights.

In the latter phases of the project, Turkish Airlines will continue to take passenger satisfaction to even higher levels and continue to advice its passengers about healthy living.

Please visit #flygoodfeelgood for The Dr. Oz Show that took place in midair and http://www.flygoodfeelgood.com/en/ for detailed information on Fly Good Feel Good.

Turkish Airlines, Inc.
Media Relations

Download more images and video here: bit.ly/2uZNUPp

Turkish Airlines Inc.
Office of Media Relations
General Management Building
34149, Yesilköy-Istanbul
Tel:  +90 (212) 463 63 63 – 11153 / 11173
Fax: +90 (212) 465 20 78
press@thy.com 


Dr. Mehmet Oz aboard TK1 from Istanbul to New York

Video – http://mma.prnewswire.com/media/538548/Turkish_Airlines_Flight_Video.mp4 
Photo – http://mma.prnewswire.com/media/538546/Turkish_Airlines_Dr_Mehmet_Oz.jpg 
Photo – http://mma.prnewswire.com/media/538594/TurkishAirlinesLogo.jpg 

PRNews

Frost & Sullivan Awards Gala Draws in Top Industry Leaders for Prestigious Recognition

Outstanding company achievements recognized at Frost & Sullivan Awards Ceremony

MOUNTAIN VIEW, California, July 20, 2017 /PRNewswire/ — Frost & Sullivan honored recipients at its Excellence in Best Practices Awards Gala held July 19th in Nashville, TN at the Loews Vanderbilt Hotel.

The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future.

“Frost & Sullivan’s Awards program has now been recognizing companies for more than fifteen years,” said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan. “These Awards come from the rigor used by our talented team of 2,000 thought leaders from over 50 global offices working with over 200,000 clients, to locate the best.”

Awarded companies included:

ACI Worldwide – 2017 United States Digital Payments Customer Value Leadership Award

Aprima Medical Software – 2017 United States Ambulatory Revenue Cycle Management Product Leadership Award

AT&T – 2017 United States Business Metro Carrier Ethernet Services Market Leadership Award

AutoGravity Corporation – 2017 North American Digital Automotive Financing Entrepreneurial Company of the Year Award

bioMérieux – 2017 Global Automated Nucleic Acid Extraction New Product Innovation Award

Bio-Microbics, Inc. – 2017 North American Integrated Water Treatment Technology Leadership Award

Cisco Systems – 2017 Global Network Firewall Market Leadership Award

CliniOps – 2017 North American Digitalization of Clinical Trials Technology Leadership Award

CytoSorbents Corporation – 2017 Global Blood Purification Product Leadership Award

DataRPM – 2017 North American Cognitive Predictive Maintenance in Automotive Manufacturing Technology Leadership Award

Drivewyze, Inc. – 2017 North American Weigh Station Bypass Company of the Year Award

Ekahau – 2017 Global Wi-Fi Network Planning, Deployment, Verification & Troubleshooting Customer Value Leadership Award

FourKites, Inc. – 2017 North American Dynamic Supply Chain Tracking Solutions Entrepreneurial Company of the Year Award

Impinj – 2017 North American RFID Solutions in Healthcare Customer Value Leadership Award

INXPO, Inc. – 2017 Global Web Event Services Growth Excellence Leadership Award

IriTech, Inc. – 2017 North American Biometrics-as-a-Service New Product Innovation Award

MercuryGate International, Inc. – 2017 North American Cloud TMS for Retail Product Leadership Award

MobileIron – 2017 North American Enterprise Mobility Management Product Line Strategy Leadership Award

Omnify Software – 2017 North American PLM for the Mid-sized Medical Devices Customer Value Leadership Award 

Oracle – 2017 North American Health Data Warehousing Product Leadership Award

Pilgrim Quality Solutions, Inc. – 2017 North American Enterprise Quality Management Solution for Pharmaceutical Product Leadership Award

Proscia – 2017 Global Cloud-Based Digital Pathology Enabling Technology Leadership Award

Qualys, Inc. – 2017 Global Vulnerability Management Market Leadership Award

Sonus Networks – 2017 North American Enterprise Session Border Controller Company of the Year Award

Spectrum Enterprise – 2017 United States Business Carrier Ethernet Services Competitive Strategy Innovation and Leadership Award

Swissray International, Inc. – 2017 Global Magnetic Resonance Imaging Price/Performance Value Leadership Award

The Sente Group, Inc. – 2017 North American Test Resource Management Software Customer Value Leadership Award

TMEIC – 2016 Global PV Inverter Company of the Year Award

ToolsGroup – 2017 North American Supply Chain Management for Retail & Wholesale Technology Leadership Award

TruTag Technologies, Inc. – 2017 North American Product Authentication Technology Innovation Award

Unisys – 2017 North American Automated Encrypted Network Security Solution Customer Value Leadership Award

Virtual Hold Technology – 2017 North American Contact Center Software New Product Innovation Award

VirtualHealth – 2017 North American Population Health Management Product Leadership Award

Vodafone Group – 2017 European Cloud Communications and Contact Centers Company of the Year Award

Xerafy – 2017 Global RFID Surgical Instrument Tracking New Product Innovation Award

Yamaha Corporation – 2016 Global Tabletop Audio Conferencing Endpoint Growth Excellence Leadership Award

Yokogawa Electric Corporation – 2017 Global Automation Solutions and Services Customer Value Leadership Award

Zang, an Avaya Company – 2017 North American Communications Platforms as a Service New Product Innovation Award

Zendrive – 2017 North American User-Based Insurance Product Leadership Award

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices.

For further information about the Awards Gala, please contact a member of the Best Practices Team.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry

I2E makes natural language processing-based text mining intuitive and interactive

SANTA CLARA, California, July 20, 2017 /PRNewswire/ — Based on its recent analysis of the Big Data text analytics market for the healthcare industry, Frost & Sullivan recognizes Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership. Linguamatics stands out in the natural language processing (NLP) market for its technology expertise and commitment to delivering exceptional value to clients in the US healthcare industry. The highly flexible and scalable Linguamatics Health platform, powered by I2E, is helping healthcare providers and payers to transition to value-based care.

Within the last year, Linguamatics introduced its fifth iteration of I2E, which includes cutting-edge capabilities such as the normalization of concepts and relationships for quick and comprehensive data retrieval regardless of format; advanced range research; and an extraction and search query language (EASL). The EASL can be generated external to the platform to support custom interfaces, queries in a human-readable format, and superior workflow automation.

“Linguamatics I2E is designed to identify the various nuances of language, such as understanding the difference between ‘history of cancer’ and ‘family history of cancer.’ Further, the I2E 5.0 release identifies precise numerical information in context, like the tumor size and medication dosages,” said Frost & Sullivan Transformational Health Principal Industry Analyst Victor Camlek. “The platform can cluster and categorize multiple concepts based on plugged-in terminologies, thesauri, or ontologies. It finds the perfect balance between linguistic context and medical text negation, ensuring that a search of ‘no evidence of pneumonia’ does not result in a diagnosis of ‘pneumonia.'”

Linguamatics also recently introduced the I2E Asynchronous Messaging Pipeline (I2E AMP) to help healthcare professionals find critical clinical insights faster. With I2E AMP, the Linguamatics platform can automate the Big Data mining of streams of data across multiple servers, providing organizations with scalability as their NLP text mining requirements grow.

Linguamatics I2E is highly flexible and can mine data from many types of data sources, including electronic health records (EHRs), clinical trial and news feeds, medical literature, social media, and lifestyle data. The platform can be deployed as an in-house enterprise system, as a value-add enterprise search capability, or as a software-as-a-service (SaaS) on the cloud. In addition to real-time processing of Big Data, I2E also provides powerful linguistic and data exploration techniques that allow patterns of language to be explored and new ontologies to be boot-strapped from basic principles, such as representations of social determinants of health within discharge summaries.

Linguamatics collaborates closely with health systems to incorporate functionalities that reduce physicians’ manual efforts, while providing real-time point-of-care clinical decision support. The platform provides varied inquiry options, ranging from entity extraction to complete linguistic analysis. An entire patient profile can be built using the right combination of smaller queries, and intelligent searches can lead to the creation of smart queries that can be deployed for a larger user base.

“With its flexibility, transparency, and speed, the I2E platform gives users complete control so they can refine searches on-the-go,” noted Camlek. “Query creation is completely configurable, ensuring that clinical users or business users do not need to be NLP or technical experts. Additionally, for advanced searches, an intuitive drag-and-drop graphical interface helps users view and manage the required queries.”

Overall, for developing a technology that a wide range of companies in the healthcare industry can adopt to create better solutions for their customers, Frost & Sullivan is pleased to present Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Linguamatics

Linguamatics transforms unstructured big data into big insights to advance human health and wellbeing. A world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support, Linguamatics’ solutions are used by top commercial, academic and government organizations, including 18 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and US National Cancer Institute, Cancer Research UK, and leading US healthcare organizations.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

Exit mobile version